Title,Authors,Platform,Cited_url,Cited_count,Year
Personal omics profiling reveals dynamic molecular and medical phenotypes,"R Chen, GI Mias, J Li-Pook-Than, L Jiang, HYK Lam, R Chen, E Miriami, ...","Cell 148 (6), 1293-1307",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9507974777168246853,998,2012
Pharmacogenomics knowledge for personalized medicine,"M Whirl‐Carrillo, EM McDonagh, JM Hebert, L Gong, K Sangkuhl, ...","Clinical Pharmacology & Therapeutics 92 (4), 414-417",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9839285417624814811,997,2012
Doxorubicin pathways: pharmacodynamics and adverse effects,"CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ...","Pharmacogenetics and genomics 21 (7), 440",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7850226821714328409,711,2011
Clinical assessment incorporating a personal genome,"EA Ashley, AJ Butte, MT Wheeler, R Chen, TE Klein, FE Dewey, ...","The Lancet 375 (9725), 1525-1535",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13431184763950420692,688,2010
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing,"MV Relling, EE Gardner, WJ Sandborn, K Schmiegelow, CH Pui, SW Yee, ...","Clinical Pharmacology & Therapeutics 89 (3), 387-391","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13020907127125745603,10227662731681560660",645,2011
CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network,"MV Relling, TE Klein","Clinical Pharmacology & Therapeutics 89 (3), 464-467",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=813292567749277915,604,2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for ,"JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ...","Clinical Pharmacology & Therapeutics 90 (4), 625-629",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2675577533195437540,572,2011
"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical …","SS Kalia, K Adelman, SJ Bale, WK Chung, C Eng, JP Evans, GE Herman, ...","Genetics in medicine 19 (2), 249","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1515944708835917558,14824353878337702369",566,2017
Clinical Pharmacogenetics Implementation Consortium Guidelines for ,"SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ...","Clinical Pharmacology & Therapeutics 94 (3), 317-323",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9048358862125140238,560,2013
Integrating genotype and phenotype information: an overview of the PharmGKB project,"TE Klein, JT Chang, MK Cho, KL Easton, R Fergerson, M Hewett, Z Lin, ...","The pharmacogenomics journal 1 (3), 167",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3111374433342850449,417,2001
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (,"SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ...","CliniCal pharmaCology & TherapeuTiCs 90 (2), 328-332",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12841027494614615573,413,2011
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update,"KR Crews, A Gaedigk, HM Dunnenberger, JS Leeder, TE Klein, ...","Clinical Pharmacology & Therapeutics 95 (4), 376-382",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6184130033558282976,404,2014
Clinical interpretation and implications of whole-genome sequencing,"FE Dewey, ME Grove, C Pan, BA Goldstein, JA Bernstein, H Chaib, ...","Jama 311 (10), 1035-1045",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15642939554663082902,393,2014
PharmGKB: the pharmacogenetics knowledge base,"M Hewett, DE Oliver, DL Rubin, KL Easton, JM Stuart, RB Altman, ...","Nucleic acids research 30 (1), 163-165",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9649497571352874532,366,2002
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for ,"JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ...","Clinical Pharmacology & Therapeutics 98 (2), 127-134",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7325469735398353245,345,2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of ,"KR Crews, A Gaedigk, HM Dunnenberger, TE Klein, DD Shen, ...","Clinical Pharmacology & Therapeutics 91 (2), 321-326",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16571441083992638027,325,2012
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups,"NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ...","Blood 115 (18), 3827-3834",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13691576767942190895,321,2010
Metformin pathways: pharmacokinetics and pharmacodynamics,"L Gong, S Goswami, KM Giacomini, RB Altman, TE Klein","Pharmacogenetics and genomics 22 (11), 820",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11640866382318615147,290,2012
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing,"KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, ...","Clinical Pharmacology & Therapeutics 94 (6), 640-645",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6483009696050065474,279,2013
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for ,"RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ...","Clinical Pharmacology & Therapeutics 92 (1), 112-117",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2808757213580917672,272,2012
The pharmacogenetics research network: from SNP discovery to clinical drug response,"KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ...","Clinical Pharmacology & Therapeutics 81 (3), 328-345",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13054207835808888033,255,2007
"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","LM Hodges, SM Markova, LW Chinn, JM Gow, DL Kroetz, TE Klein, ...","Pharmacogenetics and genomics 21 (3), 152",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11243722872821920806,239,2011
Challenges in the clinical application of whole-genome sequencing,"KE Ormond, MT Wheeler, L Hudgins, TE Klein, AJ Butte, RB Altman, ...","The Lancet 375 (9727), 1749-1751",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11049444656011428567,233,2010
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers,"HM Dunnenberger, KR Crews, JM Hoffman, KE Caudle, U Broeckel, ...","Annual review of pharmacology and toxicology 55, 89-106",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15976662956778845195,229,2015
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process,"K E Caudle, T E Klein, J M Hoffman, D J Muller, M Whirl-Carrillo, L Gong, ...","Current drug metabolism 15 (2), 209-217",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6780468053992130348,227,2014
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing,"KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ...","Clinical Pharmacology & Therapeutics 98 (1), 19-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4892354419221759277,217,2015
The Clinical Pharmacogenetics Implementation Consortium Guideline for ,"LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ...","Clinical Pharmacology & Therapeutics 96 (4), 423-428",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13183895405373959321,217,2014
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study,"MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ...","The Lancet 382 (9894), 790-796",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16345370499527645621,186,2013
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen‐B genotype and allopurinol dosing,"MS Hershfield, JT Callaghan, W Tassaneeyakul, T Mushiroda, CF Thorn, ...","Clinical Pharmacology & Therapeutics 93 (2), 153-158",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7975831917531230969,183,2013
Molecular graphics and QSAR in the study of enzyme-ligand interactions. On the definition of bioreceptors,"C Hansch, TE Klein","Accounts of Chemical Research 19 (12), 392-400",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15170851273061440405,171,1986
Prediction of CYP2D6 phenotype from genotype across world populations,"A Gaedigk, K Sangkuhl, M Whirl-Carrillo, T Klein, JS Leeder","Genetics in Medicine 19 (1), 69",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17353048324689499215,170,2017
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource,"EM McDonagh, M Whirl-Carrillo, Y Garten, RB Altman, TE Klein","Biomarkers in medicine 5 (6), 795-806",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=512031967895137708,167,2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update,"JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ...","Clinical Pharmacology & Therapeutics 102 (3), 397-404",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2529917799697290823,164,2017
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC),"KE Caudle, HM Dunnenberger, RR Freimuth, JF Peterson, JD Burlison, ...","Genetics in Medicine 19 (2), 215",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=87651341329457087,164,2017
Warfarin pharmacogenetics,"NA Limdi, DL Veenstra",Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28 (9 …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4410947865956327279,164,2008
Cytochrome P450 2C9-CYP2C9,"D Van Booven, S Marsh, H McLeod, MW Carrillo, K Sangkuhl, TE Klein, ...","Pharmacogenetics and genomics 20 (4), 277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13707079487510317373,161,2010
Conic: A fast renderer for spacefilling molecules with shadows,"CC Huang, EF Pettersen, TE Klein, TE Ferrin, R Langridge","Journal of molecular graphics 9 (4), 230-236",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10781621566698242324,159,1991
Clopidogrel pathway,"K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (7), 463",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8486883980251761172,153,2010
Clinical Pharmacogenetics Implementation Consortium Guidelines for ,"MA Martin, TE Klein, BJ Dong, M Pirmohamed, DW Haas, DL Kroetz","Clinical Pharmacology & Therapeutics 91 (4), 734-738",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2637151864149309664,152,2012
 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations,"MA Province, MP Goetz, H Brauch, DA Flockhart, JM Hebert, R Whaley, ...","Clinical Pharmacology & Therapeutics 95 (2), 216-227",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16747529762601972378,151,2014
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA‐B genotypes and phenytoin dosing,"KE Caudle, AE Rettie, M Whirl‐Carrillo, LH Smith, S Mintzer, MTM Lee, ...","Clinical Pharmacology & Therapeutics 96 (5), 542-548",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5561457981472600266,143,2014
PharmGKB summary: cyclosporine and tacrolimus pathways,"JM Barbarino, CE Staatz, R Venkataramanan, TE Klein, RB Altman","Pharmacogenetics and genomics 23 (10), 563",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17339915619814677782,141,2013
Challenges for biomedical informatics and pharmacogenomics,"RB Altman, TE Klein","Annual review of pharmacology and toxicology 42 (1), 113-133",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10722563263308662891,141,2002
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update,"JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, ...","Clinical Pharmacology & Therapeutics 102 (1), 37-44","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10399718909105974315,14458191648721935753",138,2017
The pharmacogenomics research network translational pharmacogenetics program: overcoming challenges of real‐world implementation,"AR Shuldiner, MV Relling, JF Peterson, K Hicks, RR Freimuth, W Sadee, ...","Clinical Pharmacology & Therapeutics 94 (2), 207-210",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7101404397235226901,135,2013
Valproic acid pathway: pharmacokinetics and pharmacodynamics,"Y Ghodke-Puranik, CF Thorn, JK Lamba, JS Leeder, W Song, ...","Pharmacogenetics and genomics 23 (4), 236",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11971681591004374327,131,2013
PharmGKB: the pharmacogenomics knowledge base,"CF Thorn, TE Klein, RB Altman","Pharmacogenomics, 311-320",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12025120831002006328,128,2013
Phased whole-genome genetic risk in a family quartet using a major allele reference sequence,"FE Dewey, R Chen, SP Cordero, KE Ormond, C Caleshu, KJ Karczewski, ...","PLoS genetics 7 (9), e1002280",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9935976593765779743,126,2011
Pharmacogenomics and bioinformatics: PharmGKB,"CF Thorn, TE Klein, RB Altman","Pharmacogenomics 11 (4), 501-505",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9024054036021431855,115,2010
"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","SA Scott, K Sangkuhl, AR Shuldiner, JS Hulot, CF Thorn, RB Altman, ...","Pharmacogenetics and genomics 22 (2), 159",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16892986163487289320,113,2012
Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype–phenotype relationships,"DL Bodian, TF Chan, A Poon, U Schwarze, K Yang, PH Byers, PY Kwok, ...","Human molecular genetics 18 (3), 463-471",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4277645771385004766,109,2008
WebFEATURE: an interactive web tool for identifying and visualizing functional sites on macromolecular structures,"MP Liang, DR Banatao, TE Klein, DL Brutlag, RB Altman","Nucleic acids research 31 (13), 3324-3327",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12250864631022201646,107,2003
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge,"T Hernandez-Boussard, M Whirl-Carrillo, JM Hebert, L Gong, R Owen, ...","Nucleic acids research 36 (suppl_1), D913-D918",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9073440442353791762,100,2007
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses,"LL Mazaleuskaya, K Sangkuhl, CF Thorn, GA FitzGerald, RB Altman, ...","Pharmacogenetics and genomics 25 (8), 416",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14775033259771602260,94,2015
PharmGKB,"CF Thorn, TE Klein, RB Altman","Pharmacogenomics, 179-191","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5653119670528360579,1417106950805518387",94,2005
Clinical Pharmacogenetics Implementation Consortium Guidelines for ,"MA Martin, JM Hoffman, RR Freimuth, TE Klein, BJ Dong, M Pirmohamed, ...","Clinical Pharmacology & Therapeutics 95 (5), 499-500",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13392564633537475976,91,2014
Nomenclature for alleles of the thiopurine methyltransferase gene,"ML Appell, J Berg, J Duley, WE Evans, MA Kennedy, L Lennard, ...","Pharmacogenetics and genomics 23 (4), 242",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5023266044155827102,91,2013
Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting,"LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ...","Clinical Pharmacology & Therapeutics 99 (2), 172-185",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10846695680660560539,89,2016
Implementing personalized medicine: development of a cost‐effective customized pharmacogenetics genotyping array,"JA Johnson, BM Burkley, TY Langaee, MJ Clare‐Salzler, TE Klein, ...","Clinical Pharmacology & Therapeutics 92 (4), 437-439",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16527799910622877417,87,2012
PharmGKB summary: fluoropyrimidine pathways,"CF Thorn, S Marsh, MW Carrillo, HL McLeod, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (4), 237",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10325360934057890548,86,2011
Codeine and morphine pathway,"CF Thorn, TE Klein, RB Altman","Pharmacogenetics and genomics 19 (7), 556-558",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9181007655341900770,86,2009
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response,"JM Biernacka, K Sangkuhl, G Jenkins, RM Whaley, P Barman, A Batzler, ...","Translational psychiatry 5 (4), e553",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5618974312403678776,84,2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update,"U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ...","Clinical Pharmacology & Therapeutics 103 (2), 210-216",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13594629867356263176,82,2018
PharmGKB summary: very important pharmacogene information for CYP3A5,"J Lamba, JM Hebert, EG Schuetz, TE Klein, RB Altman","Pharmacogenetics and genomics 22 (7), 555",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15699057887131628824,82,2012
PharmGKB summary: methotrexate pathway,"TS Mikkelsen, CF Thorn, JJ Yang, CM Ulrich, D French, G Zaza, ...","Pharmacogenetics and genomics 21 (10), 679",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5823053343349931879,82,2011
PharmGKB: understanding the effects of individual genetic variants,"K Sangkuhl, DS Berlin, RB Altman, TE Klein","Drug metabolism reviews 40 (4), 539-551",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10491987892356341541,82,2008
A new set of molecular mechanics parameters for hydroxyproline and its use in molecular dynamics simulations of collagen‐like peptides,"S Park, RJ Radmer, TE Klein, VS Pande","Journal of computational chemistry 26 (15), 1612-1616",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2326937268371563134,82,2005
VKORC1 pharmacogenomics summary,"RP Owen, L Gong, H Sagreiya, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (10), 642",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3818153298568652986,81,2010
Cytochrome P450 2D6,"RP Owen, K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 19 (7), 559",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16222970595338281722,80,2009
A quantitative structure-activity relationship and molecular graphics study of carbonic anhydrase inhibitors.,"C Hansch, J McClarin, T Klein, R Langridge","Molecular pharmacology 27 (5), 493-498",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8482950857779689323,80,1985
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy,"B Moriyama, AO Obeng, J Barbarino, SR Penzak, SA Henning, SA Scott, ...","Clinical Pharmacology & Therapeutics 102 (1), 45-51",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5830420073935122183,79,2017
Clopidogrel: a case for indication‐specific pharmacogenetics,"JA Johnson, DM Roden, LJ Lesko, E Ashley, TE Klein, AR Shuldiner","Clinical Pharmacology & Therapeutics 91 (5), 774-776",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4002725840663668412,76,2012
Platelet aggregation pathway,"K Sangkuhl, AR Shuldiner, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (8), 516",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4628266291159563535,73,2011
Pharmacogenetics of warfarin: challenges and opportunities,"MTM Lee, TE Klein","Journal of human genetics 58 (6), 334",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18051084576399402342,72,2013
Thiopurine pathway,"G Zaza, M Cheok, N Krynetskaia, C Thorn, G Stocco, JM Hebert, ...","Pharmacogenetics and genomics 20 (9), 573",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=634392672396075835,72,2010
Automating data acquisition into ontologies from pharmacogenetics relational data sources using declarative object definitions and XML,"DL Rubin, M Hewett, DE Oliver, TE Klein, RB Altman","Biocomputing 2002, 88-99",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9188841566877268378,72,2001
Celecoxib pathways: pharmacokinetics and pharmacodynamics,"L Gong, CF Thorn, MM Bertagnolli, T Grosser, RB Altman, TE Klein","Pharmacogenetics and genomics 22 (4), 310",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2685126630429838347,70,2012
Very important pharmacogene summary ADRB2,"AA Litonjua, L Gong, QL Duan, J Shin, MJ Moore, ST Weiss, JA Johnson, ...","Pharmacogenetics and genomics 20 (1), 64",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7670533835240373821,70,2010
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (,"A Gaedigk, M Ingelman‐Sundberg, NA Miller, JS Leeder, M Whirl‐Carrillo, ...","Clinical Pharmacology & Therapeutics 103 (3), 399-401",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11558592878691991335,68,2018
Clinically available pharmacogenomics tests,"DA Flockhart, T Skaar, DS Berlin, TE Klein, AT Nguyen","Clinical Pharmacology & Therapeutics 86 (1), 109-113",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10345072159222553405,68,2009
Predicting the clinical lethality of osteogenesis imperfecta from collagen glycine mutations,"DL Bodian, B Madhan, B Brodsky, TE Klein","Biochemistry 47 (19), 5424-5432",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17866501080421651390,66,2008
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing,"RS Gammal, CE Haidar, OF Iwuchukwu, AH Gaur, M Alvarellos, ...","Clinical Pharmacology & Therapeutics 99 (4), 363-369",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11948244667660031414,65,2016
Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy,"MP Goetz, K Sangkuhl, HJ Guchelaar, M Schwab, M Province, ...","Clinical Pharmacology & Therapeutics 103 (5), 770-777",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6871255808922228057,64,2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update,"Y Saito, LK Stamp, KE Caudle, MS Hershfield, EM McDonagh, ...","Clinical Pharmacology & Therapeutics 99 (1), 36-37",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1908123949306944077,64,2016
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype,"MV Relling, EM McDonagh, T Chang, KE Caudle, HL McLeod, CE Haidar, ...","Clinical Pharmacology & Therapeutics 96 (2), 169-174",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10273981353695973881,64,2014
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2,"EM McDonagh, S Boukouvala, E Aklillu, DW Hein, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (8), 409",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3415004935360992037,61,2014
PharmGKB summary: very important pharmacogene information for UGT1A1,"JM Barbarino, CE Haidar, TE Klein, RB Altman","Pharmacogenetics and genomics 24 (3), 177",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8501637691990430381,61,2014
Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group,"PCD Bank, KE Caudle, JJ Swen, RS Gammal, M Whirl‐Carrillo, TE Klein, ...","Clinical Pharmacology & Therapeutics 103 (4), 599-618",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10470475022799781688,59,2018
A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge,"DL Rubin, CF Thorn, TE Klein, RB Altman","Journal of the American Medical Informatics Association 12 (2), 121-129",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10825313632522782310,57,2005
Computational investigations of structural changes resulting from point mutations in a collagen‐like peptide,"TE Klein, CC Huang","Biopolymers: Original Research on Biomolecules 49 (2), 167-183",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2546854894300587978,55,1999
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for ,"AJ Muir, L Gong, SG Johnson, MTM Lee, MS Williams, TE Klein, ...","Clinical Pharmacology & Therapeutics 95 (2), 141-146",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17661342432285600654,54,2014
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans,"R Daneshjou, ER Gamazon, B Burkley, LH Cavallari, JA Johnson, ...","Blood 124 (14), 2298-2305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8676239723301517394,53,2014
PharmGKB summary: caffeine pathway,"CF Thorn, E Aklillu, EM McDonagh, TE Klein, RB Altman","Pharmacogenetics and genomics 22 (5), 389",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13842649411890888340,53,2012
PharmGKB very important pharmacogene: SLCO1B1,"C Oshiro, L Mangravite, T Klein, R Altman","Pharmacogenetics and genomics 20 (3), 211",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14565493397249332456,53,2010
Conformational preferences of substituted prolines in the collagen triple helix,"SD Mooney, PA Kollman, TE Klein","Biopolymers: Original Research on Biomolecules 64 (2), 63-71",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16001078800847424621,53,2002
Microenvironment analysis and identification of magnesium binding sites in RNA,"DR Banatao, RB Altman, TE Klein","Nucleic acids research 31 (15), 4450-4460",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5568893306971147973,52,2003
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on ,"MV Relling, M Schwab, M Whirl‐Carrillo, G Suarez‐Kurtz, CH Pui, ...","Clinical Pharmacology & Therapeutics 105 (5), 1095-1105",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7390296029982452780,51,2019
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems,"JA Luzum, RE Pakyz, AR Elsey, CE Haidar, JF Peterson, M Whirl‐Carrillo, ...","Clinical Pharmacology & Therapeutics 102 (3), 502-510",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3405150797109281490,51,2017
The functional importance of disease-associated mutation,"SD Mooney, TE Klein","BMC bioinformatics 3 (1), 24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3083071116199179988,51,2002
PharmGKB summary: tramadol pathway,"L Gong, UM Stamer, MV Tzvetkov, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (7), 374",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5910941669549667869,50,2014
"PharmGKB summary: tamoxifen pathway, pharmacokinetics","DJ Klein, CF Thorn, Z Desta, DA Flockhart, RB Altman, TE Klein","Pharmacogenetics and genomics 23 (11), 643",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=871142625121414595,50,2013
Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy,"RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ...","Clin Pharmacol Ther 92 (1), 112-117",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2437746247988563630,50,2012
Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC),"JM Hoffman, HM Dunnenberger, J Kevin Hicks, KE Caudle, ...","Journal of the American Medical Informatics Association 23 (4), 796-801",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8100250502728109107,49,2016
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base,"TE Klein, RB Altman","The pharmacogenomics journal 4 (1), 1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6577507827541329993,49,2004
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron,"GC Bell, KE Caudle, M Whirl-Carrillo, RJ Gordon, K Hikino, CA Prows, ...","Clinical pharmacology and therapeutics 102 (2), 213",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6190184793960081323,47,2017
PharmGKB summary: ibuprofen pathways,"LL Mazaleuskaya, KN Theken, L Gong, CF Thorn, GA FitzGerald, ...","Pharmacogenetics and genomics 25 (2), 96",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6481350823415356703,47,2015
Natural variation in four human collagen genes across an ethnically diverse population,"TF Chan, A Poon, A Basu, NR Addleman, J Chen, A Phong, PH Byers, ...","Genomics 91 (4), 307-314",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12656037265917540662,46,2008
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular …,"CD Selassie, Z Fang, R Li, C Hansch, G Debnath, T Klein, R Langridge, ...","Journal of medicinal chemistry 32 (8), 1895-1905",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15023758415863699424,46,1989
PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single‐drug pharmacogenetics,"RP Owen, RB Altman, TE Klein","Human mutation 29 (4), 456-460",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1953802220661298131,45,2008
PharmGKB summary: very important pharmacogene information for CYP2B6,"CF Thorn, JK Lamba, V Lamba, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (8), 520",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1317652178928099770,44,2010
Very important pharmacogene summary: thiopurine S-methyltransferase,"L Wang, L Pelleymounter, R Weinshilboum, JA Johnson, JM Hebert, ...","Pharmacogenetics and genomics 20 (6), 401",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8938630317744875174,44,2010
Computed Free energy differences between point mutations in a collagen‐like peptide,"SD Mooney, CC Huang, PA Kollman, TE Klein","Biopolymers: Original Research on Biomolecules 58 (3), 347-353",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2914617517574446460,44,2001
Quantitative structure-activity relationships and molecular graphics in ligand receptor interactions: amidine inhibition of trypsin.,"M Recanatini, T Klein, CZ Yang, J McClarin, R Langridge, C Hansch","Molecular pharmacology 29 (4), 436-446",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6496673278908655317,44,1986
Improving data and knowledge management to better integrate health care and research,"M Cases, LI Furlong, J Albanell, RB Altman, R Bellazzi, S Boyer, A Brand, ...","Journal of internal medicine 274 (4), 321-328",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10962759323631449936,43,2013
PharmGKB summary: very important pharmacogene information for CYP1A2,"CF Thorn, E Aklillu, TE Klein, RB Altman","Pharmacogenetics and genomics 22 (1), 73",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5513311453441434694,43,2012
PharmGKB summary: carbamazepine pathway,"CF Thorn, SG Leckband, J Kelsoe, JS Leeder, DJ Müller, TE Klein, ...","Pharmacogenetics and genomics 21 (12), 906",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10778590267439468004,43,2011
Selective serotonin reuptake inhibitors (SSRI) pathway,"K Sangkuhl, T Klein, R Altman","Pharmacogenetics and genomics 19 (11), 907",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2977347540157962293,43,2009
Ontology development for a pharmacogenetics knowledge base,"DE Oliver, DL Rubin, JM Stuart, M Hewett, TE Klein, RB Altman","Biocomputing 2002, 65-76",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8190280280210762152,43,2001
Bisphosphonates pathway,"L Gong, RB Altman, TE Klein","Pharmacogenetics and genomics 21 (1), 50",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5046194897145565256,41,2011
Taxane pathway,"C Oshiro, S Marsh, H McLeod, M Carrillo, T Klein, R Altman","Pharmacogenetics and genomics 19 (12), 979",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5041867725450791903,41,2009
PharmGKB: an integrated resource of pharmacogenomic data and knowledge,"L Gong, RP Owen, W Gor, RB Altman, TE Klein","Current protocols in bioinformatics 23 (1), 14.7. 1-14.7. 17",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8054435860218043947,41,2008
Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN,G Suarez-Kurtz,"The pharmacogenomics journal 4 (6), 347","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5983707247688812035,17717328479854126389,7247903790693975230",41,2004
Severity of osteogenesis imperfecta and structure of a collagen-like peptide modeling a lethal mutation site,"RJ Radmer, TE Klein","Biochemistry 43 (18), 5314-5323",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2370602613106045203,41,2004
Platinum pathway,"S Marsh, H McLeod, E Dolan, SJ Shukla, CA Rabik, L Gong, ...","Pharmacogenetics and genomics 19 (7), 563",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8814981906130370578,40,2009
Etoposide pathway,"J Yang, A Bogni, EG Schuetz, M Ratain, ME Dolan, H McLeod, L Gong, ...","Pharmacogenetics and genomics 19 (7), 552-553",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14668113174737508640,39,2009
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase,"C Hansch, T Klein, J McClarin, R Langridge, NW Cornell","Journal of medicinal chemistry 29 (5), 615-620",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9211586029945380104,39,1986
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of ,"JP Clancy, SG Johnson, SW Yee, EM McDonagh, KE Caudle, TE Klein, ...","Clinical Pharmacology & Therapeutics 95 (6), 592-597",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15918115946975633060,38,2014
Evidence and resources to implement pharmacogenetic knowledge for precision medicine,"KE Caudle, RS Gammal, M Whirl-Carrillo, JM Hoffman, MV Relling, ...","American Journal of Health-System Pharmacy 73 (23), 1977-1985",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4738600757535984102,37,2016
Very important pharmacogene summary for VDR,"AH Poon, L Gong, C Brasch-Andersen, AA Litonjua, BA Raby, Q Hamid, ...","Pharmacogenetics and genomics 22 (10), 758",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2967331245952477410,37,2012
Evidence for clinical implementation of pharmacogenomics in cardiac drugs,"AL Kaufman, J Spitz, M Jacobs, M Sorrentino, S Yuen, K Danahey, ...","Mayo Clinic Proceedings 90 (6), 716-729",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10609013034919376049,36,2015
PharmGKB summary: phenytoin pathway,"CF Thorn, M Whirl-Carrillo, JS Leeder, TE Klein, RB Altman","Pharmacogenetics and genomics 22 (6), 466",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13628638064402868301,35,2012
Clinical Pharmacogenetics Implementation Consortium Guideline for ,"EJ Phillips, C Sukasem, M Whirl‐Carrillo, DJ Müller, HM Dunnenberger, ...","Clinical Pharmacology & Therapeutics 103 (4), 574-581",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3850321585410403783,34,2018
Triple helical structure and stabilization of collagen-like molecules with 4 (R)-hydroxyproline in the Xaa position,"RJ Radmer, TE Klein","Biophysical journal 90 (2), 578-588",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9902412216863695097,34,2006
Indexing pharmacogenetic knowledge on the World Wide Web,"RB Altman, DA Flockhart, ST Sherry, DE Oliver, DL Rubin, TE Klein","Pharmacogenetics and Genomics 13 (1), 3-5",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8275473139087167954,34,2003
[24] Quantitative structure-activity relationships and molecular graphics in evaluation of enzyme-ligand interactions,"C Hansch, TE Klein","Methods in enzymology 202, 512-543",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1093345777269506584,34,1991
Genotype-Guided Dosing of Vitamin K Antagonists (Dr. Maitland-Van Der Zee and colleagues reply),"AH Maitland-van Der Zee, A De Boer, VG Manolopoulos","New England Journal of Medicine 370 (18), 1765-1766",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4083364484055979774,33,2014
Integrated tools for structural and sequence alignment and analysis,"CC Huang, WR Novak, PC Babbitt, AI Jewett, TE Ferrin, TE Klein","Biocomputing 2000, 230-241",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11747877916201220980,33,1999
The object technology framework: an object-oriented interface to molecular data and its application to collagen.,"CC Huang, GS Couch, EF Pettersen, TE Ferrin, AE Howard, TE Klein","Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 349-361",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5231165488591062251,33,1998
Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects,"S Volpi, CJ Bult, RL Chisholm, PA Deverka, GS Ginsburg, HJ Jacob, ...","Clinical Pharmacology & Therapeutics 103 (5), 778-786",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9024217128347994226,32,2018
Using ODIN for a PharmGKB revalidation experiment,"F Rinaldi, S Clematide, Y Garten, M Whirl-Carrillo, L Gong, JM Hebert, ...",Database 2012,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12114993018864944120,32,2012
"PharmGKB Summary-Very Important Pharmacogene Information for Cytochrome P-450, Family 2, Subfamily A, polypeptide 6 (CYP2A6)","EM McDonagh, C Wassenaar, SP David, RF Tyndale, RB Altman, ...","Pharmacogenetics and genomics 22 (9), 695",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1477330218487791347,31,2012
"The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge","AE Hodge, RB Altman, TE Klein","Clinical Pharmacology & Therapeutics 81 (1), 21-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10524403897169611704,31,2007
PharmGKB summary: gemcitabine pathway,"ML Alvarellos, J Lamba, K Sangkuhl, CF Thorn, L Wang, DJ Klein, ...","Pharmacogenetics and genomics 24 (11), 564",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9146970429697675429,30,2014
PharmGKB summary: citalopram pharmacokinetics pathway,"K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (11), 769",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8448219262138034260,30,2011
A functional analysis of disease‐associated mutations in the androgen receptor gene,"SD Mooney, TE Klein, RB Altman, MA Trifiro, B Gottlieb","Nucleic acids research 31 (8), e42-e42",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9196006697212901276,30,2003
Finding relevant biomolecular features.,"L Hunter, TE Klein","ISMB, 190-197",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12939947989077809498,30,1993
Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen …,"M Goetz, D Berry, T Klein, ...","Cancer Research 69 (24 Supplement), 33-33",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4363697254262523890,29,2009
"Quantitative structure− activity relationships of 2, 4-Diamino-5-(2-X-benzyl) pyrimidines versus bacterial and avian dihydrofolate reductase","CD Selassie, WX Gan, LS Kallander, TE Klein","Journal of medicinal chemistry 41 (22), 4261-4272",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10020884324711550352,29,1998
"Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2, 4-diaminopyrimidines. A QSAR and graphics analysis","CD Selassie, ZX Fang, RL Li, C Hansch, T Klein, R Langridge, ...","Journal of medicinal chemistry 29 (5), 621-626",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10346434732162171683,29,1986
Inhibition of carbonic anhydrase by substituted benzenesulfonamides. A reinvestigation by QSAR and molecular graphics analysis,"A Carotti, C Raguseo, F Campagna, R Langridge, TE Klein","Quantitative Structure‐Activity Relationships 8 (1), 1-10",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3338544872923554579,28,1989
PharmGKB: a worldwide resource for pharmacogenomic information,"JM Barbarino, M Whirl‐Carrillo, RB Altman, TE Klein","Wiley Interdisciplinary Reviews: Systems Biology and Medicine 10 (4), e1417",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5845693321089254963,27,2018
A prototype molecular interactive collaborative environment (MICE),"PE Bourne, M Gribskov, G Johnson, J Moreland, H Weissig","Pacific Symposium on Biocomputing, 118-129",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=178088870850280404,27,1998
PharmGKB summary: methylene blue pathway,"EM McDonagh, JM Bautista, I Youngster, RB Altman, TE Klein","Pharmacogenetics and genomics 23 (9), 498",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1276427688369336446,26,2013
Folding and misfolding of the collagen triple helix: Markov analysis of molecular dynamics simulations,"S Park, TE Klein, VS Pande","Biophysical journal 93 (12), 4108-4115",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4756291951125579309,25,2007
PharmGKB summary: mycophenolic acid pathway,"V Lamba, K Sangkuhl, K Sanghavi, A Fish, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (1), 73",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3018453825567692432,24,2014
PharmGKB summary: venlafaxine pathway,"K Sangkuhl, JC Stingl, M Turpeinen, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (1), 62",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10030843938424169775,24,2014
Pathway analysis of genome-wide data improves warfarin dose prediction,"R Daneshjou, NP Tatonetti, KJ Karczewski, H Sagreiya, S Bourgeois, ...","BMC genomics 14 (3), S11",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14255999334850713193,24,2013
PharmGKB summary: very important pharmacogene information for G6PD,"EM McDonagh, CF Thorn, JM Bautista, I Youngster, RB Altman, TE Klein","Pharmacogenetics and genomics 22 (3), 219",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18064854199692432007,24,2012
Genome-wide association study of warfarin maintenance dose in a Brazilian sample,"EJ Parra, MR Botton, JA Perini, S Krithika, S Bourgeois, TA Johnson, ...","Pharmacogenomics 16 (11), 1253-1263",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3610017656112248285,23,2015
"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8","CL Aquilante, M Niemi, L Gong, RB Altman, TE Klein","Pharmacogenetics and genomics 23 (12), 721",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2821358763168128606,23,2013
Challenges in the pharmacogenomic annotation of whole genomes,"RB Altman, M Whirl‐Carrillo, TE Klein","Clinical Pharmacology & Therapeutics 94 (2), 211-213",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14847955112708530253,23,2013
Structural models of osteogenesis imperfecta-associated variants in the COL1A1 gene,"SD Mooney, TE Klein","Molecular & Cellular Proteomics 1 (11), 868-875",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5561224261410399319,23,2002
A real-time malleable molecular surface,"TE Klein, CC Huang, EF Pettersen, GS Couch, TE Ferrin, R Langridge","Journal of Molecular Graphics 8 (1), 16-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11316227901810253804,23,1990
"PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2","DS Berlin, K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (5), 308",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1155442431505651609,22,2011
Sequence to medical phenotypes: a framework for interpretation of human whole genome DNA sequence data,"FE Dewey, ME Grove, JR Priest, D Waggott, P Batra, CL Miller, M Wheeler, ...","PLoS genetics 11 (10), e1005496",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14707496137435117237,21,2015
SLC19A1 pharmacogenomics summary,"SW Yee, L Gong, I Badagnani, KM Giacomini, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (11), 708",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4731492108747033232,21,2010
The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB),"RP Owen, TE Klein, RB Altman","Clinical Pharmacology & Therapeutics 82 (4), 472-475",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12877471529522888250,21,2007
Biomedical informatics training at Stanford in the 21st century,"RB Altman, TE Klein","Journal of biomedical informatics 40 (1), 55-58",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18255610699116590493,21,2007
Evidence synthesis and guideline development in genomic medicine: current status and future prospects,"SD Schully, TK Lam, WD Dotson, CQ Chang, N Aronson, ML Birkeland, ...","Genetics in Medicine 17 (1), 63",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16364081720654544731,18,2014
Very important pharmacogene summary: sulfotransferase 1A1,"M Hildebrandt, A Adjei, R Weinshilboum, JA Johnson, DS Berlin, TE Klein, ...","Pharmacogenetics and genomics 19 (6), 404-406",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16369838471519473081,18,2009
Photoaffinity analogs of methotrexate as folate antagonist binding probes. 1. Photoaffinity labeling of murine L1210 dihydrofolate reductase and amino acid sequence of the …,"EM Price, PL Smith, TE Klein, JH Freisheim","Biochemistry 26 (15), 4751-4756",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9151987826391240348,18,1987
Developing retinal biomarkers of neurological disease: an analytical perspective,"IJC MacCormick, G Czanner, B Faragher","Biomarkers in medicine 9 (7), 691-701","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14273569261646611129,7477750815238490881,6900292622482277931",17,2015
Vascular endothelial growth factor pathway,"ML Maitland, XJ Lou, J Ramirez, AA Desai, DS Berlin, HL McLeod, ...","Pharmacogenetics and genomics 20 (5), 346",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6881873347445350730,17,2010
PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme,"CF Thorn, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (2), 143",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17349414648754248030,17,2010
The structure-activity relationship of the papain hydrolysis of N-benzoylglycine esters,"CM Compadre, C Hansch, TE Klein, R Langridge",Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5500362566364889192,16,1990
Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward,"KE Caudle, NJ Keeling, TE Klein, M Whirl-Carrillo, VM Pratt, JM Hoffman","Pharmacogenomics 19 (10), 847-860",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11909187983059788969,15,2018
New Pharmacogenomics Research Network: an open community catalyzing research and translation in precision medicine,"MV Relling, RM Krauss, DM Roden, TE Klein, DM Fowler, N Terada, L Lin, ...","Clinical Pharmacology & Therapeutics 102 (6), 897-902",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6040779797280712413,15,2017
"PharmGKB Summary: Efavirenz Pathway, Pharmacokinetics (PK)","EM McDonagh, JL Lau, M Alvarellos, RB Altman, TE Klein","Pharmacogenetics and genomics 25 (7), 363",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9337701310491973427,15,2015
PharmGKB summary: very important pharmacogene information for CYP4F2,"ML Alvarellos, K Sangkuhl, R Daneshjou, M Whirl-Carrillo, RB Altman, ...","Pharmacogenetics and genomics 25 (1), 41",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5979904416074544453,15,2015
PATH-SCAN: a reporting tool for identifying clinically actionable variants,"R Daneshjou, Z Zappala, KIM KUKURBA, SM Boyle, KE Ormond, ...","Biocomputing 2014, 229-240",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3032756780800448948,15,2014
Clinical implementation of pharmacogenetics: more than one gene at a time,"JA Johnson, TE Klein, MV Relling","Clinical Pharmacology & Therapeutics 93 (5), 384-385",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7601787678581471489,15,2013
Chymotrypsin hydrolysis of X-phenyl hippurates. A quantitative structure-activity relationship and molecular graphics analysis.,"L Morgenstern, M Recanatini, TE Klein, W Steinmetz, CZ Yang, ...","Journal of Biological Chemistry 262 (22), 10767-10772",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16115848109026839272,15,1987
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (,"JT Brown, JR Bishop, K Sangkuhl, EL Nurmi, DJ Mueller, JC Dinh, ...",Clinical Pharmacology & Therapeutics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9532957112116314646,14,2019
PharmGKB summary: very important pharmacogene information for PTGS2,"CF Thorn, T Grosser, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (9), 607",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9458664198699232372,14,2011
New feature: pathways and important genes from PharmGKB,"M Eichelbaum, RB Altman, M Ratain, TE Klein","Pharmacogenetics and genomics 19 (6), 403",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13959714216696150772,14,2009
Macromolecular docking of a three-body system: The recognition of human growth hormone by its receptor,"DK Hendrix, TE Klein, ID Kuntz","Protein science 8 (5), 1010-1022",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2802051098528482231,14,1999
PharmCAT: A pharmacogenomics clinical annotation tool,"TE Klein, MD Ritchie","Clinical Pharmacology & Therapeutics 104 (1), 19-22",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8320714634594103751,13,2018
"PharmGKB Summary: Isoniazid Pathway, Pharmacokinetics (PK)","DJ Klein, S Boukouvala, EM McDonagh, SR Shuldiner, N Laurieri, ...","Pharmacogenetics and genomics 26 (9), 436",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10954351315956730241,13,2016
"PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics","EM McDonagh, CF Thorn, JT Callaghan, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (9), 464",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10892656481806024562,13,2014
PharmGKB summary: very important pharmacogene information for epidermal growth factor receptor (EGFR),"U Hodoglugil, MW Carrillo, JM Hebert, N Karachaliou, RC Rosell, ...","Pharmacogenetics and genomics 23 (11), 636",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5073898189445564849,13,2013
Computer-assisted drug receptor mapping analysis,"TE Klein, C Huang, TE Ferrin, R Langridge, C Hansch","Acs Symposium Series 306, 147-158",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2394369349206819853,13,1986
Pharmacogene variation consortium gene introduction: NUDT15,"JJ Yang, M Whirl‐Carrillo, SA Scott, AJ Turner, M Schwab, Y Tanaka, ...","Clinical pharmacology and therapeutics 105 (5), 1091",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8145392131126813303,12,2019
The Evolution of PharmVar.,"A Gaedigk, K Sangkuhl, M Whirl-Carrillo, GP Twist, TE Klein, NA Miller","Clinical pharmacology and therapeutics 105 (1), 29-32",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8583942804341454439,12,2019
Interpreting the CYP2D6 results from the international tamoxifen pharmacogenetics consortium,"MA Province, RB Altman, TE Klein","Clinical Pharmacology & Therapeutics 96 (2), 144-146",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6057629665479692722,12,2014
PharmGKB summary: dopamine receptor D2,"H Mi, PD Thomas, HZ Ring, R Jiang, K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (6), 350",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8075091266656133323,12,2011
Molecular dynamics simulations of the full triple helical region of collagen type I provide an atomic scale view of the protein's regional heterogeneity,"DL Bodian, RJ Radmer, S Holbert, TE Klein","Biocomputing 2011, 193-204",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2180345855349246072,12,2011
"PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics","ML Alvarellos, EM McDonagh, S Patel, HL McLeod, RB Altman, TE Klein","Pharmacogenetics and genomics 25 (12), 622",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=139798360651692822,11,2015
PharmGKB Summary: Very Important Pharmacogene Information for Human Leukocyte Antigen B (HLA-B),"JM Barbarino, DL Kroetz, TE Klein, RB Altman","Pharmacogenetics and genomics 25 (4), 205",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14494424286399898750,11,2015
Genome-wide Association Study of Virologic Response with Efavirenz-or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols,"DS Lehmann, HJ Ribaudo, ES Daar, RM Gulick, RH Haubrich, ...","Pharmacogenetics and genomics 25 (2), 51",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17583897741027197284,11,2015
KCNH2 pharmacogenomics summary,"C Oshiro, CF Thorn, DM Roden, TE Klein, RB Altman","Pharmacogenetics and genomics 20 (12), 775",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3105584541853411147,11,2010
Integrating large-scale genotype and phenotype data,"T Hernandez-Boussard, M Woon, TE Klein, RB Altman","Omics: a journal of integrative biology 10 (4), 545-554",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16313143806135259344,11,2006
A multidomain TIGR/olfactomedin protein family with conserved structural similarity in the N-terminal region and conserved motifs in the C-terminal region,"ML Green, TE Klein","Molecular & Cellular Proteomics 1 (5), 394-403",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12590019626847525352,11,2002
Latent periodicity of DNA sequences of many genes,"EV Korotkov, DA Phoenix","Proceedings of Pacific Symposium on Biocomputing 97, 222-229",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17304176505515795067,11,1996
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel …,"TO Bergmeijer, JL Reny, RE Pakyz, L Gong, JP Lewis, EY Kim, D Aradi, ...","American heart journal 198, 152-159",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1382516343143419185,10,2018
Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges,"R Daneshjou, Y Wang, Y Bromberg, S Bovo, PL Martelli, G Babbi, ...","Human mutation 38 (9), 1182-1192",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10297714936762434474,10,2017
"PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics","D Lowenberg, CF Thorn, Z Desta, DA Flockhart, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (2), 133",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13069337941943432062,10,2014
PharmGKB: very important pharmacogene–HMGCR,"MW Medina, K Sangkuhl, TE Klein, RB Altman","Pharmacogenetics and genomics 21 (2), 98",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3566152470490457528,10,2011
"COLdb, a database linking genetic data to molecular function in fibrillar collagens","DL Bodian, TE Klein","Human mutation 30 (6), 946-951",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1000668136522725977,10,2009
Pathway-based approaches to pharmacogenomics,"CF Thorn, M Whirl-Carrillo, TE Klein, RB Altman","Current Pharmacogenomics 5 (1), 79-86",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10788998257511869453,10,2007
Association of the polygenic scores for personality traits and response to selective serotonin reuptake inhibitors in patients with major depressive disorder,"AT Amare, KO Schubert, F Tekola-Ayele, YH Hsu, K Sangkuhl, G Jenkins, ...","Frontiers in psychiatry 9, 65",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10627713775019888645,9,2018
PharmGKB summary: sorafenib pathways,"L Gong, MM Giacomini, C Giacomini, ML Maitland, RB Altman, TE Klein","Pharmacogenetics and genomics 27 (6), 240",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12814233812958642355,9,2017
PharmGKB summary: zidovudine pathway,"Y Ghodke, PL Anderson, K Sangkuhl, J Lamba, RB Altman, TE Klein","Pharmacogenetics and genomics 22 (12), 891",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11897649480185619640,9,2012
DNATwist: A Web‐Based Tool for Teaching Middle and High School Students About Pharmacogenomics,"DS Berlin, MG Person, A Mittal, MA Oppezzo, DB Chin, B Starr, TE Klein, ...","Clinical Pharmacology & Therapeutics 87 (4), 393-395",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17463181386903637999,9,2010
A resource to acquire and summarize pharmacogenetics knowledge in the literature.,"DL Rubin, MW Carrillo, M Woon, J Conroy, TE Klein, RB Altman","Medinfo, 793-797",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4047269963222662018,9,2004
Computer-aided drug discovery: From target proteins to drug candidates,"J Bajorath, TE Klein, TP Lybrand, J Novotny","Biocomputing'99, 413-414",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11988260467549387212,9,1999
A molecular dynamics study of the inhibition of chicken dihydrofolate reductase by a phenyl triazine,"AR Leach, TE Klein","Journal of computational chemistry 16 (11), 1378-1393",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7164613013017033347,9,1995
"F., BARCLAY RK and HAMiLTON L. D","M Feughelman, R LAiNGRIDGE, WE Seeds, AR Stokes, HR Wilson, ...","Nature 175, 834",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14909090854471217159,9,1955
"PharmGKB summary: voriconazole pathway, pharmacokinetics","JM Barbarino, A Owusu-Obeng, TE Klein, RB Altman","Pharmacogenetics and genomics 27 (5), 201",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8972148800397042605,8,2017
PharmGKB summary: very important pharmacogene information for RYR1,"ML Alvarellos, RM Krauss, RA Wilke, RB Altman, TE Klein","Pharmacogenetics and genomics 26 (3), 138",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9513025814325005935,8,2016
PharmGKB summary-very important pharmacogene information for GSTT1,"CF Thorn, Y Ji, RM Weinshilboum, RB Altman, TE Klein","Pharmacogenetics and genomics 22 (8), 646",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5115336486003895329,8,2012
Separation of electronic and hydrophobic effects for the papain hydrolysis of substituted N-benzoylglycine esters,"CM Compadre, C Hansch, TE Klein, J Petridou-Fischer, CD Selassie, ...",Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1586965548511693527,8,1991
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for ,"Z Desta, RS Gammal, L Gong, M Whirl‐Carrillo, AH Gaur, C Sukasem, ...",Clinical Pharmacology & Therapeutics,"https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6620844421432206490,12488108482079113821",7,2019
Pharmacogenomics and big genomic data: from lab to clinic and back again,"A Lavertu, G McInnes, R Daneshjou, M Whirl-Carrillo, TE Klein, ...","Human molecular genetics 27 (R1), R72-R78",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11230659548120721302,7,2018
Novel SNPs associated with warfarin dose in a large multicenter cohort of African Americans: Genome wide association study and replication results,"MA Perera, NA Limdi, L Cavallari, ER Gamazon, A Konkashbaev, ...","Circulation 124 (suppl_21), A15518-A15518",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8309615672336355172,7,2011
Antiestrogen pathway (aromatase inhibitor),"Z Desta, A Nguyen, D Flockhart, T Skaar, R Fletcher, R Weinshilboum, ...","Pharmacogenetics and genomics 19 (7), 554",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11791896586861514420,7,2009
Building bridges: QSAR and molecular graphics,"CD Selassie, TE Klein","3D QSAR in Drug Design, 257",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15324470987945818824,7,1993
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S …,"SG Gonsalves, RT Dirksen, K Sangkuhl, R Pulk, M Alvarellos, T Vo, ...","Clinical Pharmacology & Therapeutics 105 (6), 1338-1344",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14910112919839372675,6,2019
Standardized biogeographic grouping system for annotating populations in pharmacogenetic research,"R Huddart, AE Fohner, M Whirl‐Carrillo, GL Wojcik, CR Gignoux, ...","Clinical Pharmacology & Therapeutics 105 (5), 1256-1262",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11144274740009505014,6,2019
PharmGKB summary: very important pharmacogene information for MT-RNR1,"JM Barbarino, TL McGregor, RB Altman, TE Klein","Pharmacogenetics and genomics 26 (12), 558",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11931705760291596756,6,2016
PharmGKB summary: very important pharmacogene information for SLC22A1,"S Goswami, L Gong, K Giacomini, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (6), 324",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11118054548041237293,6,2014
In silico comparative characterization of pharmacogenomic missense variants,"B Li, C Seligman, J Thusberg, JL Miller, J Auer, M Whirl-Carrillo, ...","BMC genomics 15 (4), S4",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15159562282160299307,6,2014
Biocomputing 2009,"RB Altman, AK Dunker, L Hunter",World Scientific,"https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15287980772472240023,12584876191379297615",6,2008
An XML‐based interchange format for genotype–phenotype data,"M Whirl‐Carrillo, M Woon, CF Thorn, TE Klein, RB Altman","Human mutation 29 (2), 212-219",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10882272815285016831,6,2008
An “omics” view of drug development,"RB Altman, DL Rubin, TE Klein","Drug development research 62 (2), 81-85",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18380208226757598256,6,2004
ViewFeature: integrated feature analysis and visualization,"DR Banatao, CC Huang, PC Babbitt, RB Altman, TE Klein","Biocomputing 2001, 240-250",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14100166072622831355,6,2000
QSAR analysis of the subtilisin hydrolysis of X-phenyl hippurates. II. A study of subtilisin BPN′,"A Carotti, C Raguseo, TE Klein, R Langridge, C Hansch","Chemico-biological interactions 67 (3-4), 171-184",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9605347836178531802,6,1988
"The ACCO u NT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans","PN Friedman, M Shaazuddin, L Gong, RL Grossman, AF Harralson, ...","Clinical and translational science 12 (3), 209-217",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10174786965671943994,5,2019
The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression,"AT Amare, KO Schubert, F Tekola-Ayele, YH Hsu, K Sangkuhl, G Jenkins, ...","Journal of Neural Transmission 126 (1), 35-45",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17716771603310939993,5,2019
"PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics","AE Fohner, A Sparreboom, RB Altman, TE Klein","Pharmacogenetics and genomics 27 (4), 164",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12010533563028842648,5,2017
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response,"JM Biernacka, K Sangkuhl, G Jenkins, RM Whaley, P Barman, A Batzler, ...","Translational psychiatry 6 (11), e937",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13479160184710406852,5,2016
Enabling the curation of your pharmacogenetic study,"EM McDonagh, M Whirl‐Carrillo, RB Altman, TE Klein","Clinical Pharmacology & Therapeutics 97 (2), 116-119",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11628036094065112351,5,2015
Pharmacogenetics: call to action,"MV Relling, HJ Guchelaar, DM Roden, TE Klein","Clinical Pharmacology & Therapeutics 90 (4), 507-507",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12392577677034716677,5,2011
A personalized and automated dbSNP surveillance system,"S Liu, S Lin, M Woon, TE Klein, RB Altman",Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13380044101589633058,5,2003
Analysis of mutations in the colia1 gene with second-order rule induction,"R Hewett, J Leuchner, SD Mooney, TE Klein",International journal of pattern recognition and artificial intelligence 17 …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8017854851481965514,5,2003
Neural networks applied to the collagenous disease osteogenesis imperfecta,"TE Klein, E Wong",Proceedings of the Twenty-Fifth Hawaii International Conference on System …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17168603886787837228,5,1992
The Case for Pharmacogenetics‐Guided Prescribing of Codeine in Children,"RS Gammal, KE Caudle, CT Quinn, WC Wang, A Gaedigk, CA Prows, ...","Clinical Pharmacology & Therapeutics 105 (6), 1300-1302",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8683256650059189645,4,2019
PharmGKB summary: very important pharmacogene information for ABCG2,"AE Fohner, DJ Brackman, KM Giacomini, RB Altman, TE Klein","Pharmacogenetics and genomics 27 (11), 420",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=221445689498927894,4,2017
"Response to"" Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped""-The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of …","TJ Walsh, B Moriyama, SR Penzak, TE Klein, KE Caudle","Clinical pharmacology and therapeutics 102 (2), 190",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17503748717493108655,4,2017
"PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics","AE Fohner, EM McDonagh, JP Clancy, MW Carrillo, RB Altman, TE Klein","Pharmacogenetics and genomics 27 (1), 39",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4105336553569457431,4,2017
PharmGKB summary: abacavir pathway,"JM Barbarino, DL Kroetz, RB Altman, TE Klein","Pharmacogenetics and genomics 24 (5), 276",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7512637395486833246,4,2014
"PharmGKB summary: diuretics pathway, pharmacodynamics","CF Thorn, DH Ellison, ST Turner, RB Altman, TE Klein","Pharmacogenetics and genomics 23 (8), 449",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17031061689173400265,4,2013
Pharmacogenomics: the relevance of emerging genotyping technologies,"T Hernandez-Boussard, TE Klein, RB Altman","MEDICAL LABORATORY OBSERVER 38 (3), 24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11440759697680269618,4,2006
Computer graphics and molecular modeling,"TE Ferrin, TE Klein",Encyclopedia of Computational Chemistry 1,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2772663484384730004,4,2002
Comparative quantitative structure–activity relationships (QSAR) of the inhibition of dihydrofolate reductase,"CD Selassie, TE Klein","Comparative Qsar, 235-284",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6818329442384175673,4,1998
Substitutions for arginine at position 780 in triple helical domain of the α1 (I) chain alter folding of the type I procollagen molecule and cause osteogenesis imperfecta,"E Makareeva, G Sun, LS Mirigian, EL Mertz, JC Vera, NA Espinoza, ...","PloS one 13 (7), e0200264",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16519861441220496606,3,2018
"PharmGKB summary: clobazam pathway, pharmacokinetics","R Huddart, JS Leeder, RB Altman, TE Klein","Pharmacogenetics and genomics 28 (4), 110-115",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6437593205303548348,3,2018
Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure,"T Walsh, B Moriyama, S Penzak, T Klein, K Caudle",Clinical Pharmacology & Therapeutics 103 (2),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13943948624987049484,3,2018
Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans,"R Daneshjou, LH Cavallari, PE Weeke, KJ Karczewski, K Drozda, ...","Molecular genetics & genomic medicine 4 (5), 513-520",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3524330239900459137,3,2016
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network,"Y Saito, LK Stamp, KE Caudle, MS Hershfield, EM McDonagh, ...","Clinical Pharmacology and Therapeutics 99 (1), 36-37",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15514627640049404226,3,2016
The clinical pharmacogenetics implementation consortium (CPIC): facilitating the adoption of pharmacogenetics into routine clinical practice and the electronic health record.: 286.,"K Caudle, J Hoffman, M Whirl-Carrillo, C Haidar, K Crews, T Klein, ...",Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy 34 (10),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3218948821906554186,3,2014
Callaghan Jt; Clinical Pharmacogenetics implementation Consortium: Clinical pharmacogenetics implementation consortium guidelines for CyP2C9 and hLA-B genotypes and phenytoin …,"KE Caudle, AE Rettie, M Whirl-Carrillo, MS Smith Lh, KE Lee Mt","Clin Pharmacol ther 96, 542-8",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16687637031592379503,3,2014
Governmental and academic efforts to advance the field of pharmacogenomics,"LH Cavallari, TE Klein, SM Huang","Pharmacogenomics, 63-88",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11324409797633422287,3,2013
PharmGKB summary,"C Thorn, Y Ji, R Weinshilboum, R Altman, T Klein","Pharmacogenetics and Genomics 22 (8), 646-651",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17933091451402314657,3,2012
"Estimation of the warfarin dose with clinical and pharmacogenetic data (vol 360, pg 753, 2009)","TE Klein, RB Altman, N Eriksson, BF Gage, SE Kimmel, MTM Lee, ...","New England Journal of Medicine 361 (16), 1613-1613",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6006292343524556890,3,2009
BIOCOMPUTING 2017,"RB Altman, AK Dunker, L Hunter, MD Ritchie, T Murray, TE Klein",,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3008063658719028692,3,2004
Pacific Symposium on Biocomputing'97,R Altman,"Pacific Symposium on Biocomputing 1997: Maui, Hawaii)","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5789356622025744201,14032246540187950936",3,1996
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics …,"KE Caudle, K Sangkuhl, M Whirl‐Carrillo, JJ Swen, CE Haidar, TE Klein, ...",Clinical and translational science,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10397041884025539191,2,2019
PharmVar GeneReview: CYP2D6,"C Nofziger, AJ Turner, K Sangkuhl, M Whirl‐Carrillo, JAG Agúndez, ...",Clinical Pharmacology & Therapeutics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2294688018719029115,2,2019
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?,"R Huddart, K Sangkuhl, M Whirl-Carrillo, TE Klein",Clinical pharmacology and therapeutics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3456602213109028628,2,2019
Considerations for pharmacogenomic testing in a health system,"RS Gammal, KE Caudle, TE Klein, MV Relling","Genetics in Medicine, 1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6310784429263804562,2,2019
Pharmacogenomics Clinical Annotation Tool (PharmCAT),"K Sangkuhl, M Whirl‐Carrillo, RM Whaley, M Woon, A Lavertu, RB Altman, ...",Clinical Pharmacology & Therapeutics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14975555224668980773,2,2018
"PharmGKB summary: pazopanib pathway, pharmacokinetics","CF Thorn, MR Sharma, RB Altman, TE Klein","Pharmacogenetics and genomics 27 (8), 307",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3517379397584300993,2,2017
Novel Disease–Drug Database Demonstrating Applicability for Pharmacogenomic‐Based Prescribing,"M Whirl‐Carrillo, K Sangkuhl, L Gong, TE Klein","Clinical Pharmacology & Therapeutics 100 (6), 600-602",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14534355741407500902,2,2016
PharmGKB summary: very important pharmacogene information for CFTR,"EM McDonagh, JP Clancy, RB Altman, TE Klein","Pharmacogenetics and genomics 25 (3), 149",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8752410893863409297,2,2015
Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer,"MA Province, TE Klein, ...","Journal Of The National Cancer Institute 106 (2), djt379",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7041358464429366951,2,2014
Compression-Based Induction and Genome Data.,"R Hewett, JH Leuchner, CM Teng, SD Mooney, TE Klein","FLAIRS Conference, 344-348",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17786777473680299051,2,2002
Superfamily Analysis: Understanding Protein Function from Structure and Sequence,"PC Babbitt, TE Klein",Encyclopedia of Computational Chemistry 4,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5650012536115727956,2,2002
Pacific Symposium on Biocomputing 2001,T KLEIN,,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8869619281014927728,2,2001
"Management of data, knowledge, and metadata on the semantic web: Experience with a pharmacogenetics knowledge base","DE Oliver, M Hewett, DL Rubin, JM Stuart, TE Klein, RB Altman","Stanford Medical Informatics Research Reports SMI-2001–0901–1, 9th September …",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10456690943165678555,2,2001
Concanavalin X-phenyl beta-D-glucopyranoside interactions. A molecular graphics-QSAR analysis.,"M Recanatini, TE Klein, R Langridge, C Hansch","Il Farmaco; edizione scientifica 42 (12), 879-891",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9676079383910927870,2,1987
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later,"MV Relling, TE Klein, RS Gammal, M Whirl‐Carrillo, JM Hoffman, ...",Clinical Pharmacology & Therapeutics,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8884953572579608959,1,2019
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients,"JP Lewis, JD Backman, JL Reny, TO Bergmeijer, BD Mitchell, MD Ritchie, ...",European Heart Journal-Cardiovascular Pharmacotherapy,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3365796592965754247,1,2019
Essential Characteristics of Pharmacogenomics Study Publications,"CF Thorn, M Whirl‐Carrillo, H Hachad, JA Johnson, EM McDonagh, ...","Clinical Pharmacology & Therapeutics 105 (1), 86-91",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6999864448917521062,1,2019
"PharmGKB summary: oxycodone pathway, pharmacokinetics","R Huddart, M Clarke, RB Altman, TE Klein","Pharmacogenetics and genomics 28 (10), 230-237",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9121292898651703645,1,2018
"PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics","M Alvarellos, C Guillemette, RB Altman, TE Klein","Pharmacogenetics and genomics 28 (5), 127",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18029081981204541206,1,2018
PharmGKB summary,"J Barbarino, AO Obeng, T Klein, R Altman","Pharmacogenetics and Genomics 27 (5), 201-209",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2735652027034325371,1,2017
PharmGKB summary,"E McDonagh, J Lau, M Alvarellos, R Altman, T Klein","Pharmacogenetics and Genomics 25 (7), 363-376",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13484817716767428338,1,2015
Welcome to the pharmacogenomics journal,J Licinio,"The Pharmacogenomics Journal 1 (1), 1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17002855514569238438,1,2001
The Macromolecular Workbench and its application to the study of Collagen,"CC Huang, TE Klein, JH Morris, TE Ferrin, R Langridge",Proceedings of the Twenty-Fourth Annual Hawaii International Conference on …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12675954894443342940,1,1991
"KARMA, a knowledge-based system for receptor mapping",TE Klein,"University of California, San Francisco",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11320366940864379169,1,1987
COMPUTER-GRAPHICS AND ARTIFICIAL-INTELLIGENCE IN DRUG DESIGN AND PROTEIN ENGINEERING,"TE Klein, D Kneller, C Huang, ET FERRIN, R Langridge","JOURNAL OF MOLECULAR GRAPHICS 3 (3), 111-113",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15355795222068676749,1,1985
PGxMine: Text mining for curation of PharmGKB,"J Lever, JM Barbarino, L Gong, R Huddart, K Sangkuhl, R Whaley, ...","Pacific Symposium on Biocomputing 25, 611-622",,0,2020
CORRIGENDUM: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or …,"SG Gonsalves, RT Dirksen, K Sangkuhl, R Pulk, M Alvarellos, T Vo, ...","Clinical Pharmacology & Therapeutics 106 (6), 1408",,0,2019
PharmVar and the Landscape of Pharmacogenetic Resources,"A Gaedigk, M Whirl‐Carrillo, VM Pratt, NA Miller, TE Klein",Clinical Pharmacology & Therapeutics,,0,2019
A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.,"JK Hicks, JR Bishop, RS Gammal, K Sangkuhl, CA Bousman, JS Leeder, ...",Clinical pharmacology and therapeutics,,0,2019
"PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics","T Stevens, K Sangkuhl, JT Brown, RB Altman, TE Klein","Pharmacogenetics and genomics 29 (6), 136-154",,0,2019
"PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics","R Huddart, RB Altman, TE Klein","Pharmacogenetics and genomics 29 (4), 91-97",,0,2019
Pharmacogenomics in Dermatology: Tools for understanding gene-drug associations,"R Daneshjou, R Huddart, T Klein, R Altman","Seminars in cutaneous medicine and surgery 38 (1), E19",,0,2019
Pharmacogenomics Knowledge for Personalized Medicine,"T Klein, M Ritchie","EUROPEAN JOURNAL OF HUMAN GENETICS 26, 30-31",,0,2018
PharmGKB summary,"C Thorn, D Müller, R Altman, T Klein","Pharmacogenetics and Genomics 28 (9), 214-222",,0,2018
"PharmGKB summary: clozapine pathway, pharmacokinetics","CF Thorn, DJ Müller, RB Altman, TE Klein","Pharmacogenetics and genomics 28 (9), 214-222",,0,2018
"PharmGKB summary: voriconazole pathway, pharmacokinetics (vol 27, pg 201, 2017)","JM Barbarino, OA Owusu, TE Klein, RB Altman","PHARMACOGENETICS AND GENOMICS 28 (8), 198-198",,0,2018
THE PHARMACOGENE VARIATION CONSORTIUM: INCORPORATION OF THE HUMAN CYTOCHROME P450 ALLELE NOMENCLATURE DATABASE.,"A Gaedigk, TE Klein, GP Twist, M Whirl-Carrillo, NA Miller","CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S67-S67",,0,2018
"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (vol 102, pg 45, 2017)","B Moriyama, AO Obeng, J Barbarino, S Penzak, S Henning, S Scott, ...","CLINICAL PHARMACOLOGY & THERAPEUTICS 103 (2), 349-349",,0,2018
Biocomputing 2019: Proceedings of the Pacific Symposium: Pacific Symposium on Biocomputing 2019,"RB Altman, AK Dunker, L Hunter, MD Ritchie, T Murray, TE Klein",World Scientific Publishing Co.,,0,2018
Access by ACA-American Counseling Association-TPS ACCOUNT,"C Dandara, NE Thomford, TE Bapiro, E Ramírez, A Rodríguez, ...","ISI 15, 267",,0,2018
Breaking Down Barriers to Effective Patient Care,"A Gaedigk, M Ingelman-Sundberg, NA Miller, JS Leeder, M Whirl-Carrillo, ...","CLINICAL PHARMACOLOGY AND THERAPEUTICS-ST LOUIS- 103 (3), 399-401",,0,2018
PharmGKB summary,"C Thorn, M Sharma, R Altman, T Klein","Pharmacogenetics and Genomics 27 (8), 307-312",,0,2017
PharmGKB summary: peginterferon-α pathway,"SR Shuldiner, L Gong, AJ Muir, RB Altman, TE Klein","Pharmacogenetics and genomics 25 (9), 465",,0,2015
INTERACTIVE GENOTYPE-BASED DOSING GUIDELINES: PII-006,"M Whirl-Carrillo, R Whaley, K Caudle, M Relling, R Altman, T Klein",Clinical Pharmacology & Therapeutics 97,,0,2015
Pharmacogenomics of SSRI Treatment Response: Findings of the International SSRI Pharmacogenomics Consortium (ISPC),"J Biernacka, K Sangkuhl, J Stingl, M Kato, SJ Tsai, O Kampman, YL Liu, ...","NEUROPSYCHOPHARMACOLOGY 39, S575-S575",,0,2014
Biocomputing 2015: Proceedings of the Pacific Symposium,TA Murray,World Scientific Publishing Company,,0,2014
A TWENTIETH ANNIVERSARY TRIBUTE TO PSB,"D Hewett, M WHIRL-CARRILLO, LE Hunter, RB Altman, TE Klein","Pacific Symposium on Biocomputing Co-Chairs, 1-7",,0,2014
PharmGKB summary,"C Thorn, D Ellison, S Turner, R Altman, T Klein","Pharmacogenetics and Genomics 23 (8), 449-453",,0,2013
Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations: Finding Signal within the Noise,"ER Gamazon, R Daneshjou, LH Cavallari, NA Limdi, M Wadelius, ...","Clinical Pharmacology and Therapeutics 93 (S1), S27-S27",,0,2013
Personal omics profiling reveals dynamic molecular and medical phenotypes,"JF Ferguson, R Chen, GI Mias, J Li-Pook-Than, L Jiang, HY Lam, ...","Circulation: Cardiovascular Genetics 5 (3), 381-382",,0,2012
"PharmGKB, a centralized resource for pharmacogenomic knowledge and discovery","L Gong, TE Klein","Principles of Pharmacogenetics and Pharmacogenomics, 38",,0,2012
Systems Pharmacogenomics-Bridging the Gap.,"MD Ritchie, NJ Cox, C Cheng, S Weiss, TE Klein, RB Altman","Pacific Symposium on Biocomputing, 442",,0,2012
9789814366496: Proceedings of the Pacific Symposium,"RB Altman, AK Dunker, L Hunter, TA Murray, TE Klein",World Scientific Publishing Company,,0,2011
Abstract 15518,"M Perera, N Limdi, L Cavallari, E Gamazon, A Konkashbaev, ...",Circulation 124 (21_MeetingAbstracts),,0,2011
"Bourgine, Joanna; Garat, Anne; Allorge, Delphine; Crunelle-Thibaut, Aurélie; Lo-Guidice, Jean-Marc; Colombel, Jean-Frédéric; Broly, Franck; Billaut-Laden, Ingrid","L Ekström, JJ Schulze, C Guillemette, A Belanger, A Rane, ET Price, ...","Pharmacogenetics and Genomics 21 (6), 313-324",,0,2011
"Nilesh J Samani, Maciej Tomaszewski and Heribert Schunkert c","EA Ashley, AJ Butte, MT Wheeler, R Chen, TE Klein, FE Dewey, ...",The Lancet 375 (9725),,0,2010
Pacific Symposium on Biocomputing 2011 (BIOCOMPUTING 2011),"RB Altman, AK Dunker, L Hunter, T Murray, TE Klein",,,0,2010
Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients.,"FI Al-Saikhan, MAE Abd-Elaziz, RH Ashour, T Langaee, RL Seip, ...","International Journal of Pharmacology 14 (3), 409-424",,0,2010
Thiopurine pathway,"Z Gianluigi, C Meyling, K Natalia, T Caroline, G Stocco, JM Hebert, ...",,,0,2010
Warfarin Pharmacogenetics,"T Klein, S Kimmel, J Johnson",The New England Journal of Medicine 360 (23),,0,2009
Pacific Symposium on Biocomputing 2010,"AK Dunker, L Hunter, TE Klein, MD Ritchie",World Scientific,,0,2009
Pharmacogenetics/Pharmacogenomics,"XJ Lou, RB Altman, TE Klein","Bioinformatics‐From Genomes to Therapies, 1427-1455",,0,2007
PharmGED: Pharmacogenetic effect database. Commentary,"AE HODGE, RB ALTMAN, TE KLEIN, B XIE, CJ ZHENG, LY HAN, S ONG, ...",Clinical pharmacology and therapeutics 81 (1),,0,2007
Pacific symposium on biocomputing 2006,"RB Altman, A Dunker, L Hunter, TE Klein",Unknown Journal,,0,2006
"A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge (vol 12, pg 121, 2005)","DL Rubin, CF Thorn, TE Klein, RB Altman","JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 12 (3), 364-364",,0,2005
"BioPAX–Biological Pathways Exchange Language Level 1, Version 1.4 Documentation","E Brauner, MP Cary, R Goldberg, C Hogue, P Karp, T Klein, J Luciano, ...",,,0,2005
Old principles in new clothes,EE Redei,"The pharmacogenomics journal 4 (4), 219",,0,2004
"Biocomputing 2005: Proceedings of The Pacific Symposium, Hawaii, USA 4-8 January 2005","RB Altman, TA Jung, TE Klein",World Scientific,,0,2004
"Pacific Symposium on Biocomputing'99, World Scientific, New Jersey; Pacific Symposium on Biocomputing'00, World Scientific, New Jersey; Pacific Symposium on Biocomputing'01 …","RB Altman, AK Dunker, L Hunter, TE Klein, K Lauderdale","Washington State University, Pullman WA",,0,2003
Special Paper-Introduction.,"RB Altman, AK Dunker, L Hunter, TE Klein","Pacific Symposium on Biocomputing, 636-637",,0,2003
"Pacific Symposium on Biocomputing 2003: Kauai, Hawaii, 3-7 January 2003","RB Altman, AK Dunker, L Hunter",World Scientific,,0,2002
Conformational preferences of substituted proline residues in the triple helix of collagen.,"SD Mooney, PA Kollman, TE Klein","ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222, U415-U416",,0,2001
Pharmacogenomic expression profiling of psoriasis,"J Azuma, E Boerwinkle, U Brinkmann, RGH Cotton, P Froguel, F de Lille, ...","The Pharmacogenomics Journal 1, 219-220",,0,2001
"Biocomputing 2001: Proceedings of the Pacific Symposium, Mauna Lani, Hawaii, 3-7 January 2001","RB Altman, AK Dunker, L Hunker, K Lauderdale, TE Klein",World Scientific Publishing Company,,0,2000
Integrated Software Tools for Functional Genomics,"T Ferrin, P Babbitt, C Huang, T Klein","Nature 399, 517-520",,0,1999
Extending Chimera for collaborative molecular visualization,"TE Ferrin, C Huang, TE Klein","ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217, U569-U570",,0,1999
Computer-Aided Drug Design-Session Introduction.,"J Bajorath, TE Klein, TP Lybrand, J Novotny","Pacific Symposium on Biocomputing, 413-414",,0,1999
Pacific Symposium on Biocomputing 1997/1998,T Klein,"Oakland Operations Office, Oakland, CA",,0,1998
A real-time malleable surface for molecular modeling,"TE Klein, C Huang, EF Pettersen, GC Couch, TE Ferrin, R Langridge","Journal of Molecular Graphics 4 (6), 210-211",,0,1998
MOLECULAR MODELING IN DRUG DESIGN AND BIOTECHNOLOGY,"J Bajorath, TE Klein, TP Lybrand","Biocomputing'98-Proceedings Of The Pacific Symposium, 303",,0,1997
Biocomputing'98: Proceedings of the Pacific Symposium,"RB Altman, AK Dunker, L Hunter, TE Klein","Biocomputing'98: Proceedings of the Pacific Symposium, 1-784",,0,1997
Modern concepts in molecular modeling,"J Bajorath, TE Klein","World Scientific Publishing Co. Pte. Ltd., River Edge, NJ (United States)",,0,1996
Pacific symposium on biocomputing97: Proceedings,"RB Altman, AK Dunker, L Hunter, TE Klein","World Scientific Publishing Co. Pte. Ltd., River Edge, NJ (United States)",,0,1996
Biocomputing'96-Proceedings Of The Pacific Symposium,H Lawrence,World Scientific,,0,1995
PACIFIC SYMPOSIUM ON ‘,TE Klein,,,0,1995
Biocomputing: Proceedings,"L Hunter, TE Klein",World Scientific,,0,1995
"Pacific Symposium on Biocomputing'96: Hawaii, USA, 3-6 January, 1996","L Hunter, TE Klein",World Scientific,,0,1995
QSAR and Molecular Graphics in Drug Design,"C Hansch, T Klein",Frontiers in drug research: crystallographic and computational methods …,,0,1990
Introduction to Computer Graphics,"R LANGRIDGE, TE KLEIN","Comprehensive medicinal chemistry: the rational design, mechanistic study …",,0,1989
The structure selectivity problem in drug design with respect to antifolates.,"SC Dias, RL Li, CH Hansch, T Klein, R Langridge, BT Kaufman, ...","Progress in clinical and biological research 291, 341",,0,1989
PAPAIN HYDROLYSIS OF N-ALKANOYL AND N-BENZOYL GLYCINE ESTERS-A QSAR AND MOLECULAR GRAPHICS ANALYSIS,"CM COMPADRE, T KLEIN, JM BLANEY, C HANSCH","ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 196, 50-MEDI",,0,1988
REAL-TIME SURFACE REPRESENTATIONS FOR KNOWLEDGE-BASED RECEPTOR MAPPING,"TE KLEIN, C HUANG, EF PETTERSEN, TE FERRIN, R LANGRIDGE","ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 196, 70-COMP",,0,1988
MANUFACTURING,J LYMAN,"ELECTRONICS 59 (33), 105-106",,0,1986
The UCSF computer graphics laboratory: tenth anniversary progress report,"R Langridge, TE Ferrin, CC Huang, LE Jarvis, WE Jarvis, N Pattabiraman, ...","Journal of Molecular Graphics 4 (3), 179",,0,1986
"This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which …","MV Relling, M Schwab, M Whirl-Carrillo, G Suarez-Kurtz, CH Pui, ...",,,0,0
Supplemental Material Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing,"KE Caudle, AE Rettie, M Whirl-Carrillo, LH Smith, SE Mintzer, MTM Lee, ...",,,0,0
Peer Review Only,"D Monrad, M Frye, A Rush, T Klein, R Kaddurah-Daouk, R Weinshilboum",,,0,0
Supplemental Material Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update,"MV Relling, M Schwab, M Whirl-Carrillo, G Suarez-Kurtz, CH Pui, ...",,,0,0
Supplemental Material for,"L Ding, Y Li, X Zhang, J He, D Lu, X Fang, Y Wang, J Wang, Y Zhang, ...",,,0,0
Login/Sign Up,"M Whirl-Carrillo, TE Klein",,,0,0
Guideline Title,"KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, ...",,,0,0
Supplemental Material Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing,"KA Birdwell, B Decker, JM Barbarino, JF Peterson, C Michael, J Swen11, ...",,,0,0
BIOCOMPUTING'96,"L Hunter, TE Klein",,,0,0
Corresponding Author: Matthias Schwab,"GC Bell, KE Caudle, M Whirl-Carrillo, RJ Gordon, K Hikino, CA Prows, ...",,,0,0
Guideline Title,"MS Hershfield, JT Callaghan, W Tassaneeyakul, T Mushiroda, CF Thorn, ...",,,0,0
Sara Hillenmeyer,"R Daneshjou, ER Gamazon, B Burkley, LH Cavallari, JA Johnson, ...",,,0,0
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update,"JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, S Kazu, ...",,,0,0
Pharmacogenetic Resources: PharmGKB and Clinical Pharmacogenetics Implementation Consortium,"M Whirl-Carrillo, TE Klein",,,0,0
THE OBJECT TECHNOLOGY FRAMEWORK (OTF): AN OBJECT-ORIENTED INTERFACE TO MOLECULAR DATA AND ITS APPLICATION TO COLLAGEN,"AE HOWARD, TE KLEIN",,,0,0
"Addendum to Kendrick, J. and Fox, M. Calculation and display of electrostatic potentials. J. Mol. Graphics 1991, 9, 182-187",TE Klein,,,0,0
In Silico Classification and Identification of Pharmacogenetic Variants of Human Proteins,"C Seligman, J Thusberg, B Li, E Capriotti, J Auer, M Whirl-Carrillo, T Klein, ...",,,0,0
